Researchers have discovered that secondary infection with the methicillin-resistant Staphylococcus aureus (MRSA) bacterium often kills influenza patients because the flu virus alters the antibacterial response of white blood cells, causing them to damage the patients’ lungs instead of destroying the bacterium. The study, which will be published online August 15 ahead of issue in the Journal of Experimental Medicine, suggests that inhibiting this response may help treat patients infected with both the flu virus and MRSA.
The lungs of mice co-infected with both influenza and MRSA appear much healthier after combined treatment with antibiotics and an NADPH oxidase inhibitor (right) than they do after antibiotic treatment alone (left). Courtesy of Sun et al., 2016
Researchers have discovered that secondary infection with the methicillin-resistant Staphylococcus aureus (MRSA) bacterium often kills influenza patients because the flu virus alters the antibacterial response of white blood cells, causing them to damage the patients’ lungs instead of destroying the bacterium. The study, which will be published online August 15 ahead of issue in the Journal of Experimental Medicine, suggests that inhibiting this response may help treat patients infected with both the flu virus and MRSA.
Many influenza patients develop severe pneumonia as a result of secondary infections with MRSA. Over half of these patients die, even when treated with antibiotics that are usually capable of clearing MRSA infections. Keer Sun, an assistant professor at the University of Nebraska Medical Center, previously discovered that mice infected with influenza are susceptible to MRSA because the ability of their macrophages and neutrophils to kill bacteria by releasing hydrogen peroxide and other reactive oxygen species is suppressed. But it remained unclear why MRSA-infected influenza patients often die, even after receiving an appropriate antibiotic treatment.
Sun and colleagues now reveal that this may be because the patients’ white blood cells cause extensive damage to their lungs. Though the macrophages and neutrophils of mice co-infected with influenza and MRSA were defective at killing bacteria, reactive oxygen species released by these cells induced the death of inflammatory cells within the lungs, lethally damaging the surrounding tissue. Inhibiting NADPH oxidase 2 (Nox2), the enzyme that produces reactive oxygen species in macrophages and neutrophils, reduced the extent of this damage and, when combined with antibiotic treatment, boosted the survival of co-infected mice.
“Our results demonstrate that influenza infection disrupts the delicate balance between Nox2-dependent antibacterial immunity and inflammation,” says Sun. “This not only leads to increased susceptibility to MRSA infection but also extensive lung damage. Treatment strategies that target both bacteria and reactive oxygen species may significantly benefit patients with influenza-complicated MRSA pneumonia.”
Source: The Rockefeller University Press
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.